

Table: Dengue vaccine candidates in clinical development¹

Vaccine type Technological approach	Development stage Selected current trials	Developer	References²
Live attenuated vaccine YF17D/DEN chimeric viruses	Phase 3 NCT01373281 NCT01374516	Sanofi Pasteur	[1],[2]
Live attenuated vaccine Attenuated DEN2 PDK-53 virus and DEN/DEN intertypic chimeric viruses	Phase 2 NCT01511250	Inviragen	[3]
Live attenuated vaccine Targeted mutagenesis of DEN viruses and DEN/DEN intertypic chimeric virus	Phase 2 NCT01696422	Butantan Institute National Institute of Allergy and Infectious Diseases	[4],[5]
Recombinant subunit vaccine Truncated E protein	Phase 1 NCT01477580	Merck	[6]
Purified inactivated virus vaccine	Phase 1 NCT01702857 NCT01666652	GlaxoSmithKline Oswaldo Cruz Foundation Walter Reed Army Institute of Research	
DNA vaccine Expression of prM and E proteins	Phase 1 NCT01502358	Naval Medical Research Center Walter Reed Army Institute of Research	[7],[8]

¹ Active clinical development projects as of February 2013

² Selected recent publications of clinical trial results and review articles

References

1. Sabchareon, A., Wallace, D., Sirivichayakul, C., Limkittikul, K., Chanthavanich, P., Suvannadabba, S., Jiwariyavej, V., Dulyachai, W., Pengsaa, K., Wartel, T.A., et al. (2012). Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. *Lancet* 380, 1559-1567.
2. Guy, B., Barrere, B., Malinowski, C., Saville, M., Teyssou, R., and Lang, J. (2011). From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. *Vaccine* 29, 7229-41.
3. Osorio, J.E., Huang, C.Y., Kinney, R.M., and Stinchcomb, D.T. (2011). Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. *Vaccine* 29, 7251-7260.

4. Durbin, A.P., Kirkpatrick, B.D., Pierce, K.K., Elwood, D., Larsson, C.J., Lindow, J.C., Tibery, C., Sabundayo, B.P., Shaffer, D., Talaat, K.R., et al. (2013). A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naïve Adults: A Randomized, Double-blind Clinical Trial. *J Infect Dis*. Epub ahead of print 31 Jan.
5. Durbin, A.P., Kirkpatrick, B.D., Pierce, K.K., Schmidt, A.C., and Whitehead, S.S. (2011). Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. *Vaccine 29*, 7242-50
6. Collier, B.A., Clements, D.E., Bett, A.J., Sagar, S.L., and Ter Meulen, J.H. (2011). The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. *Vaccine 29*, 7267-7275.
7. Danko, J.R., Beckett, C.G., and Porter, K.R. (2011). Development of dengue DNA vaccines. *Vaccine 29*, 7261-7266.
8. Beckett, C.G., Tjaden, J., Burgess, T., Danko, J.R., Tamminga, C., Simmons, M., Wu, S.J., Sun, P., Kochel, T., Raviprakash, K., et al. (2011). Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. *Vaccine 29*, 960-968.